The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor. The exception is for cerebral edema, but dose should be < 4 mg once treatment begins. Bevacizumab can be used to control edema, but not as a biologic treatment intended for the patient’s disease under study. Subjects who, in the assessment by the investigator, require the use of any of the aforementioned treatments for clinical management should be removed from the trial.